PLX
Protalix BioTherapeutics, Inc.
$2.30
-0.02 (-0.86%)
At close · Jul 6
Market Cap
$185.31M
Shares
80,571,642
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.30
Open$2.31
Day$2.30–2.35
52W$1.36–3.19
Avg vol 30d654K
Short int3.9M · 4.9% float · 7.1d
Short vol53%
Last earningsMay 13, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+4% above
+
Price vs 50-day avg
+10% above
◦
RSI (14)
61 · neutral
+
MACD trend
positive
◦
52-week position
51% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $2 › 200d $2 — 200d above 50d
+
Institutional flow
+21% holders QoQ · +27 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
4.85% of float · ▼ -0.6% MoM · 7.1 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
99 holders — near 3-yr high, broad support
Fundamentals
Weak
−
Revenue growth
−1% Y/Y
+
Gross margin
8%, expanding
−
EPS growth
−300% Y/Y
−
Free cash flow
$-13.6M
◦
Valuation
P/E 12.1 · in line
+
Balance sheet
net cash $14.7M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 15, 2026
Est · unconfirmed
· in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 13, 2026
Total revenue in 2026 to range from approximately $78.0 million
· Full-year 2026
Initiated
$78M – $83M
prior FY $52.74M
midpoint +52.6% Y/Y
Full-year 2026 revenues from sales of Elfabrio without milestone
· Full-year 2026
Lowered
$33M – $35M
prior FY $52.74M
midpoint −35.5% Y/Y
Full-year 2026 revenues from sales of Elelyso
· Full-year 2026
Lowered
$20M – $23M
prior FY $52.74M
midpoint −59.2% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+4% above
Bullish
Price vs 50-day avg
+10% above
Bullish
RSI (14)
61 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
51% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+21% holders QoQ · +27 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.85% of float · ▼ -0.6% MoM · 7.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
99 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $2 · 51%
52-wk high $3
vs 200-day avg +4%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| milestone payment received from Chiesi | $25M | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PLX
this stock
Protalix BioTherapeutics, Inc.
|
$185.31M | +27.8% | -1.2% | 12.1 | 4.9% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PLX | +0.0% | +14.4% | +11.1% | -1.3% | +27.8% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -1.4% | +15.7% | +3.1% | -1.0% | +18.6% |